Isracann Biosciences Inc. · OTC:ISCNF
Isracann Biosciences — Investor Presentation (November 2018)
16 slides from Isracann Biosciences's investor presentation, November 2018
Slide 1: Israel's First Pure-Play Cannabis Firm
Israel’s First Pure- Play Cannabis Firm Corporate Presentation
Slide 2: Legal
Legal Information contained in this presentation is the property of Isracann Biosciences Inc. (Isracann or the “Company”). This presentation does not constitute, or form part of, any offer or invitation to sell or issue, or any solicitation of any offer to subscribe for or purchase any securities in
Slide 3: About Isracann: Israel's First Pure-Play Cannabis Firm
About IIIIIIIIIIIII C I Israel’s First Pure-Play Cannabis Firm Isracann, Israel’s first pure-play cannabis firm, is focused on becoming a premier, low-cost cannabis producer. Isracann has secured 3 farms in Israel with cultivation licenses totalling 580,000 sq. ft. Located in the cannabis research c
Slide 4: The Opportunity in Israel
The Opportunity in Israel Optimal climatic conditions to grow medical cannabis Ideal Optimal Approx. 300 days High Humidity Temperature of Sun per Year UV rays Safeguarding the plant Reduces energy in winter and Optimal sun exposure Vital for effective growth from insects and enabling summer, saving
Slide 5: Investment Highlights
Investment Highlights Facility Licensed Secured deals with 3 licensed farms in Israel to lease their land for medicinal marijuana cultivation, all currently hold cultivation licenses Significant Size Fully funded capacity of 232,900 sq. ft. with the ability to produce 23,500 kg annually. Expansion O
Slide 6: Investment Highlights
Investment Highlights Location Low-cost Operations Optimal climate and infrastructure allow for greenhouses and low-cost production of approx. $0.40/gram Leading Research Centre Researchers in Israel have been studying cannabis for 50 years Agricultural Innovation Israel is world renowned as an agri
Slide 7: Investment Highlights
Investment Highlights Market Cannabis One of the fastest growing consumer segments ever, with an estimated global market size of $146.6B by 2025 Domestic 10,000 patients in Israel currently on waitlist. Massively underserved domestic market presents significant and immediate opportunity Internationa
Slide 8: Business Model: Four Pillars
Business Model: Four Pillars Isracann believes in four verticals to leverage its expertise and scale its business R&D Partnership with Lumir Labs Branding at Hebrew University of Jerusalem to leverage their Distribution A centre for innovation and expertise and bring novel excellence, Israel’s well-
Slide 9: Israel's Regulatory Overview
Israel’s Regulatory Overview In 2007 Israel became the first country to allow medical research and cannabis cultivation Cannabis is legal for medical purposes in Israel and decriminalized for recreational use Export approval announced and anticipated in 2019 Similar to Canada, a massive opportunity
Slide 10: Israeli Market
Israeli Market Optimal climate for growing conditions will allow Isracann to be a low-cost producer serving the domestic market Haifa 10,000 patients on waitlist for medical cannabis due to supply constraints Tel Aviv Patients expected to exceed 50,000 in 2019 Jerusalem Among the highest cannabis us
Slide 11: European Market
European Market After Israel announces its legislative framework for exports, Isracann intends to become a premier supplier of the European market Medical cannabis already available in 10 European countries Europe population over 740 million, double USA and Canada —the two largest cannabis markets t
Slide 12: The Facility
The Facility Fully funded for 232,900 sq. ft. with annual capacity of 23,500 kg with ability to scale to 580,000 sq. ft Low-cost producer of high-grade medical marijuana, with anticipated cost of $0.40 per gram Partnership with Yamko, a global construction leader based in Israel and established in 1
Slide 13: Sector Comparables
Sector Comparables Market Cap ($MM) Funded Facility Size Market Cap ($MM)/ Market Cap ($MM) Company Name Funded Capacity (1,000 sq. ft.) Funded Facility Size /Funded Capacity (Nov. 9, 2018) Isracannn Biosciences $55.2MM 232.9 23.5t 0.2x 2.3x WeedMD $179MM 616.0 33.0t 0.3x 5.4x Newstrike $284MM 374.0
Slide 14: Proposed Timeline
Proposed Timeline 2018/2019 Q4 Q1 Q2 Q3 Q4 1 2 3 4 5 6 7 8 9 19 11 12 13 14 15 Architecture Engineering Security Design Building Permits R&D Partnership Product Development Greenhouse Construction Nursery Propagation Planting Harvest GMP Facility 14 Confidential
Slide 15: Capitalization Table
Share Class No. of Shares Value AKE:CSE 38,315,000 $19,541,000 Isracann Biosciences Inc. 70,000,000 $35,700,000 Capitalization Table Pre-Money 108,315,000 $55,241,000 Financing (@$0.51) 19,608,000 $10,000,000 Post-Money 127,923,000 $65,241,000 Cash Balance $15,000,000 Post-Financing 15 Confidential
Slide 16: Thank You
Thank You Darryl Jones, President +1.604.788.9533 djones@isracann.com www.isracann.com Isracann Biosciences Inc. 1600-595 Burrard Street Vancouver, BC V7X 1L3 Canada
Isracann Biosciences — Investor Presentation (November 2018) on 6ix